Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$16.77 -2.4%	$18.49	$14.15 ▼ $20.68	$2.80B	0.43	2.59 million shs	1.63 million shs
AVXL Anavex Life Sciences	$8.90 -0.9%	$9.48	$3.25 ▼ $14.44	$757.07M	0.94	1.26 million shs	954,472 shs
VCEL Vericel	$45.81 -4.2%	$56.02	$39.12 ▼ $63.00	$2.29B	1.78	423,104 shs	532,587 shs
XENE Xenon Pharmaceuticals	$35.48 +2.1%	$38.81	$33.27 ▼ $46.00	$2.72B	1.26	376,200 shs	305,115 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-2.44%	-7.25%	-11.18%	-2.84%	-16.07%
AVXL Anavex Life Sciences	-0.89%	+1.95%	+1.02%	+7.23%	+71.15%
VCEL Vericel	-4.18%	-11.10%	-21.89%	-19.65%	+3.18%
XENE Xenon Pharmaceuticals	+2.07%	-4.55%	-9.61%	-10.06%	-19.82%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.4942 of 5 stars	4.3	3.0	0.0	3.0	4.2	2.5
AVXL Anavex Life Sciences	3.838 of 5 stars	3.7	1.0	4.7	2.6	0.8	0.6
VCEL Vericel	2.4018 of 5 stars	3.5	1.0	0.0	2.1	0.8	1.9
XENE Xenon Pharmaceuticals	2.1021 of 5 stars	3.5	2.0	0.0	2.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.53	Moderate Buy	$24.00	43.11% Upside
AVXL Anavex Life Sciences	3.33	Buy	$44.00	394.38% Upside
VCEL Vericel	3.00	Buy	$62.29	35.97% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$57.38	61.71% Upside

Current Analyst Ratings Breakdown

Latest AVXL, XENE, ACAD, and VCEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/7/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight	$20.00 ➝ $20.00
3/3/2025	VCEL Vericel	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$67.00 ➝ $61.00
2/28/2025	XENE Xenon Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
2/28/2025	VCEL Vericel	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
2/28/2025	XENE Xenon Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/27/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$28.00 ➝ $28.00
2/27/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
2/27/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
2/24/2025	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00
2/18/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
2/12/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00

(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	2.92	N/A	N/A	$2.63 per share	6.38
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
VCEL Vericel	$237.22M	9.65	$0.01 per share	3,081.95	$4.73 per share	9.68
XENE Xenon Pharmaceuticals	$9.43M	287.99	N/A	N/A	$14.18 per share	2.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	-$61.29M	$1.36	21.50	22.07	N/A	13.83%	25.83%	14.71%	5/14/2025 (Estimated)
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-37.50%	-34.08%	5/8/2025 (Estimated)
VCEL Vericel	-$3.18M	$0.18	763.63	104.11	N/A	1.56%	1.48%	0.96%	5/6/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$182.39M	-$3.02	N/A	N/A	N/A	N/A	-24.69%	-23.68%	5/8/2025 (Estimated)

Latest AVXL, XENE, ACAD, and VCEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/27/2025	Q4 2024	XENE Xenon Pharmaceuticals	-$0.89	-$0.84	+$0.05	-$0.84	$0.31 million	N/A
2/12/2025	Q1 2025	AVXL Anavex Life Sciences	-$0.17	-$0.14	+$0.03	-$0.14	N/A	N/A
12/23/2024	Q4 2024	AVXL Anavex Life Sciences	-$0.17	-$0.14	+$0.03	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.29	2.11
AVXL Anavex Life Sciences	N/A	9.45	9.45
VCEL Vericel	N/A	4.61	4.23
XENE Xenon Pharmaceuticals	N/A	22.21	22.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
AVXL Anavex Life Sciences	31.55%
VCEL Vericel	N/A
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
AVXL Anavex Life Sciences	11.00%
VCEL Vericel	7.20%
XENE Xenon Pharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	166.79 million	119.30 million	Optionable
AVXL Anavex Life Sciences	40	85.06 million	75.71 million	Optionable
VCEL Vericel	300	49.97 million	46.79 million	Optionable
XENE Xenon Pharmaceuticals	210	76.54 million	72.03 million	Optionable

AVXL, XENE, ACAD, and VCEL Headlines

Recent News About These Companies

Xenon to Present at Stifel 2025 Virtual CNS Forum

March 12 at 4:19 PM | financialpost.com

Xenon to Present at Stifel 2025 Virtual CNS Forum

March 12 at 4:01 PM | globenewswire.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $57.38 Average Target Price from Brokerages

March 10 at 1:51 AM | americanbankingnews.com

FMR LLC's Strategic Acquisition of Xenon Pharmaceuticals Inc. Shares

March 7, 2025 | gurufocus.com

Candriam S.C.A. Purchases 28,320 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

March 7, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Brokerages

March 7, 2025 | marketbeat.com

Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)

March 6, 2025 | americanbankingnews.com

Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

March 6, 2025 | marketbeat.com

Wedbush Has Negative Outlook for XENE FY2028 Earnings

March 4, 2025 | americanbankingnews.com

FY2028 EPS Estimate for Xenon Pharmaceuticals Cut by Analyst

March 3, 2025 | marketbeat.com

Q1 Earnings Forecast for XENE Issued By William Blair

March 3, 2025 | americanbankingnews.com

Q1 Earnings Forecast for XENE Issued By HC Wainwright

March 3, 2025 | marketbeat.com

Equities Analysts Offer Predictions for XENE Q1 Earnings

March 3, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Given Outperform Rating at William Blair

March 3, 2025 | americanbankingnews.com

What is Leerink Partnrs' Estimate for XENE Q1 Earnings?

March 3, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 12-Month Low - Time to Sell?

March 1, 2025 | marketbeat.com

Xenon Pharmaceuticals' (XENE) "Outperform" Rating Reaffirmed at William Blair

March 1, 2025 | marketbeat.com

Xenon Pharmaceuticals’ Earnings Call Highlights Progress and Challenges

March 1, 2025 | msn.com

Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

February 28, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc.: Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update

February 28, 2025 | finanznachrichten.de

Xenon Pharmaceuticals price target lowered to $42 from $43 at Wedbush

February 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, XENE, ACAD, and VCEL Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$16.77 -0.42 (-2.44%)

Closing price 03/12/2025 04:00 PM Eastern

Extended Trading

$17.20 +0.43 (+2.56%)

As of 03/12/2025 07:00 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Anavex Life Sciences NASDAQ:AVXL

$8.90 -0.08 (-0.89%)

Closing price 03/12/2025 04:00 PM Eastern

Extended Trading

$8.84 -0.06 (-0.67%)

As of 03/12/2025 07:10 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Vericel NASDAQ:VCEL

$45.81 -2.00 (-4.18%)

Closing price 03/12/2025 04:00 PM Eastern

Extended Trading

$45.81 0.00 (0.00%)

As of 03/12/2025 04:42 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Xenon Pharmaceuticals NASDAQ:XENE

$35.48 +0.72 (+2.07%)

Closing price 03/12/2025 04:00 PM Eastern

Extended Trading

$35.48 +0.00 (+0.00%)

As of 03/12/2025 05:00 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time